Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1152Prostatic Neoplasms 642Neoplasms 581Carcinoma, Non-Small-Cell Lung 488Multiple Myeloma 482Leukemia, Myeloid, Acute 461Leukemia 418Lung Neoplasms 399Lymphoma 381Leukemia, Lymphocytic, Chronic, B-Cell 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Lymphoma, Non-Hodgkin 326Colorectal Neoplasms 310Pancreatic Neoplasms 306Neoplasm Metastasis 302Myelodysplastic Syndromes 301Melanoma 286Hodgkin Disease 253Head and Neck Neoplasms 249Brain Neoplasms 231Lymphoma, Follicular 224Ovarian Neoplasms 221Recurrence 220Glioblastoma 215Lymphoma, Mantle-Cell 211Lymphoma, Large B-Cell, Diffuse 209Squamous Cell Carcinoma of Head and Neck 176Colonic Neoplasms 162Carcinoma, Renal Cell 158Carcinoma, Hepatocellular 154

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Has results × Hormone-sensitive Metastatic Breast Cancer × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡